Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. One out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading down 16 points (-0.1%) at 16,836 as of Monday, June 30, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,605 issues advancing vs. 1,347 declining with 197 unchanged. The Health Services industry currently sits down 0.1% versus the S&P 500, which is unchanged. Top gainers within the industry include Abbott Laboratories ( ABT), up 0.8%, and Humana ( HUM), up 0.5%. On the negative front, top decliners within the industry include Accelerate Diagnostics ( AXDX), down 16.4%, ResMed ( RMD), down 4.0%, Edwards Lifesciences ( EW), down 1.7%, Fresenius Medical Care AG & Co. KGaA ( FMS), down 1.1% and Varian Medical Systems ( VAR), down 1.0%. TheStreet would like to highlight 3 stocks pushing the industry higher today: 3. Smith & Nephew ( SNN) is one of the companies pushing the Health Services industry higher today. As of noon trading, Smith & Nephew is up $0.58 (0.7%) to $89.23 on light volume. Thus far, 92,765 shares of Smith & Nephew exchanged hands as compared to its average daily volume of 248,300 shares. The stock has ranged in price between $88.86-$89.51 after having opened the day at $88.92 as compared to the previous trading day's close of $88.65. Smith & Nephew plc develops, manufactures, markets, and sells medical devices in the advanced surgical devices and advanced wound management sectors worldwide. Smith & Nephew has a market cap of $15.8 billion and is part of the health care sector. Shares are up 23.6% year-to-date as of the close of trading on Friday. Currently there are 5 analysts who rate Smith & Nephew a buy, no analysts rate it a sell, and 3 rate it a hold. TheStreet Ratings rates Smith & Nephew as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, increase in net income, largely solid financial position with reasonable debt levels by most measures, expanding profit margins and growth in earnings per share. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Smith & Nephew Ratings Report now. 3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.